Imaging sigma receptors: Applications in drug development

Current Pharmaceutical Design

Volumn 13, Issue 1, 2007, Pages 51-72

  Lee Collier, Thomas ^a   Waterhouse, Rikki N ^b   Kassiou, Michael ^c  

^a Siemens Molecular Imaging Biomarker Research   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Drug development; PET; Radioligand; Radiotracer; Sigma receptors; SPECT

Indexed keywords

1 (2 HYDROXYETHYL) 4 (4 IODOPHENOXYMETHYL)PIPERIDINE I 123; 1 (3 CHLORO 4 CYCLOHEXYLPHENYL) 3 (HEXAHYDRO 1 AZEPINYL)PROPENE; 1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 1 CYCLOPROPYLMETHYL 4 [2 (4 FLUOROPHENYL) 2 OXOETHYL]PIPERIDINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 4 [2 (4 CYANOPHENYL) 2 OXOETHYL] 1 (CYCLOPROPYLMETHYL)PIPERIDINE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; CLOZAPINE; EDM 57445; ELIPRODIL; HALOPERIDOL; IFENPRODIL; IGMESINE; METHADONE; N (4' FLUOROBENZYL) 4 (3 BROMOPHENYL)ACETAMIDE F 18; N (N BENZYLPIPERIDIN 4 YL) 2 FLUOROBENZAMIDE F 18; N [2 (1' PIPERIDINYL)ETHYL] 3 IODO 4 METHOXYBENZAMIDE I 123; N [2 (1' PIPERIDINYL)ETHYL] 3 IODO 4 METHOXYBENZAMIDE I 125; N ALLYLNORMETAZOCINE; N CYCLOHEXYL N ETHYL 3 (3 CHLORO 4 CYCLOHEXYLPHENYL) 2 PROPENYLAMINE; NALTREXONE; OPC 14523; PANAMESINE; PLACEBO; PRASTERONE; RADIOPHARMACEUTICAL AGENT; REMOXIPRIDE; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; SSR 125047; UNCLASSIFIED DRUG; UNINDEXED DRUG; VPI 013;

BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEMENTIA; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ELECTROCONVULSIVE THERAPY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL DISEASE; HUMAN; IC 50; IMMUNOPATHOLOGY; MAJOR DEPRESSION; MENTAL DISEASE; MOLECULAR IMAGING; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG DESIGN; GONADAL STEROID HORMONES; HUMANS; LIGANDS; MOLECULAR STRUCTURE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTROPIC DRUGS; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR MARKERS, BIOLOGICAL;

EID: 33846162759     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313740     Document Type: Review

References (323)

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197(3): 517-32.
2. Aram JA, Martin D, Tomczyk M, Zeman S, Millar J, Pohler G, et al. Neocortical epileptogenesis in vitro: studies with N-methyl-D-aspartate, phencyclidine, sigma and dextromethorphan receptor ligands. J Pharmacol Exp Ther 1989; 248(1): 320-8.
3. Martin BR, Katzen JS, Woods JA, Tripadii HL, Harris LS, May EL. Stereoisorners of [3H]-N-allyinortnetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther 1984; 231(3): 539-44.
4. Myers AM, Charifson PS, Owens CE, Kula NS, McPhail AT, Baldessarini RJ, et al. Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor. J Med Chem 1994; 37(24): 4109-17.
5. Booth RG, Owens CE, Brown RL, Bucholtz EC, Lawler CP, Wyrick SD. Putative sigma(3) sites in mammalian brain have histamine H(1) receptor properties: evidence from ligand binding and distribution studies with the novel H(1) radioligand [(3)H]-(-)-trans-1-phenyl-3-aminotetralin. Brain Res 1999; 837(1-2): 95-105.
6. Kekuda F, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 1996; 229(2): 553-8.
7. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigmal-binding site. Proc Natl Acad Sci USA 1996; 93(15): 8072-7.
8. Prasad PD, Li HW, Fei YJ, Ganapathy ME, Fujita T, Plumley LH, et al. Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type 1 sigma receptor gene. J Neurochem 1998; 70(2): 443-51.
9. Hong W, Werling LL. Evidence that the sigma(1) receptor is not directly coupled to G proteins. Eur J Pharmacol 2000; 408(2): 117-25.
10. Monnet FP, Blier P, Debonnel G, de Montipy C. Modulation by sigma ligands of N-methyl-D-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency. Naunyn Schmiedebergs Arch Pharmacol 1992; 346(1): 32-9.
11. Ramamoorthy JD, Ramamoorthy S, Mahesh VB, Leibach FH, Ganapathy V. Cocaine-sensitive sigma-receptor and its interaction with steroid hormones in the human placental syncytiotrophoblast ndd in choriocarcinoma cells. Endocrinology 1995; 136(3): 924-32.
12. Wheeler KT, Wang LM, Wallen CA, Childers SF, Cline JM, Keng PC, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000; 82(6): 1223-32.
13. Mach RH, Huang Y, Buchheimer N, Kuhner R, Wu L, Morton TE, et al. (18)F]N-(4′-fluorobenzyl)-4-(3-bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [(18)F]FDG, and [(125)I]IUDR. Nucl Med Biol 2001; 28(4): 451-8.
14. Kawamura K, Ishiwata Y, Tajimia H, Ishii S, Matsuno K, Homma Y, et al. In vivo evaluation of [(11)C]SA4503 as a PET ligand for mapping CNS sigma(l) receptors. Nucl Med Biol 2000; 27(3): 255-61.
15. Jawamura Y, Ishiwata K, Shimada Y, Kimura Y, Kobayashi T, Matsuno K, et al. Preclinical evaluation of [11C]SA4503: radiation dosimetry, in vivo selectivity and PET imaging of sigma 1 receptors in the cat brain. Ann Nucl Med 2000; 14(4): 285-92.
16. Klouz A, Loueslati MH, Daghfous R, Morin D. Are sigma receptors implicated in ischemic injury? Therapie 2001; 56(5): 557-62.
17. Kobayashi T, Matsuno K, Nakata K, Mita S. Enhancement of ace tylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain. J Pharmacol Exp Ther 1996; 279(1): 106-13.
18. Kobayashi T, Matsuno K, Murai M, Mita S. Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem Res 1997; 22(9): 1105-9.
19. Kobayashi T, Matsuno K, Mita S. Sigmal receptor subtype does not interact with stereotyped behaviors in rats. Pharmacol Biochem Behav 1998; 61(4): 381-4.
20. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 1996; 306(1-3): 271-9.
21. Matsuno K, Kobayashi T, Tanaka MK, Mita S. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996; 312(3): 267-71.
22. Matsuno K, Senda T, Kobayashi T, Okamoto K, Nakata K, Mita S. SA4503, a novel cognitive enhancer, with sigma 1 receptor agonistic properties. Behav Brain Res 1997; 83(1-2): 221-4.
23. Monnet FP, Blier P, Debormel G, de Montigny C. Modulation by sigma ligands of N-methyl-D-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency. Naunyn Schmiedebergs Arch Pharmacol 1992; 346(1): 32-9.
24. Su TP, Shukla K, Gund T. Steroid binding at sigma receptors: CNS and immunological implications. Ciba Foundation Symposium 1990; 153: 107-13; discussion 13-6.
25. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005; 65(19): 8975-83.
26. Gebreselassie D, Bowen WD. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur J Pharmacol 2004; 493(1-3): 19-28.
27. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002; 62(1): 313-22.
28. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995; 55(2): 408-13.
29. John CS, Bowen WD, Fisher SJ, Lim BB, Geyer BC, Vilner BJ, et al. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1′-piperidinyl)ethyl]-3-[1251]iodo-4-meth-oxybenzamide (P[251]MBA) for imaging breast cancer. Nucl Med Biol 1999; 26(4): 377-82.
30. John CS, Bowen WD, Varma VM, McAfee JG, Moody TW. Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sci 1995; 56(26): 2385-92.
31. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003; 10(20): 2073-80.
32. Gibbs TT, Farb DH. Dueling enigmas: neurosteroids and sigma receptors in the limelight. Sci STKE 2000; 2000(60): PE1.
33. Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev 2001; 37(1-3): 116-32.
34. Skuza G, Wedzony K. Behavioral pharmacology of sigma-ligands. Pharmacopsychiatry 2004; 37(Suppl-3): S183-8.
35. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl) 2004; 174(3): 301-19.
36. Duncan G, Wang L. Focus on molecules: the Sigma-1 receptor. Exp Eye Res 2005; 81(2): 121-2.
37. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spear 2005; 10(4): 319-23.
38. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiactric diosorders. CNS Drags 2004; 18(5): 269-84.
39. Bowen WD. Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv 2000; 74(2-3): 211-8.
40. Bolos J. Current strategies for the development of novel antipsychotic drugs. Mini Rev Med Chem 2003; 3(3): 239-51.
41. Hoffman DW. Neuroleptic drugs and the sigma receptor. Am J Psychiatry 1990; 147(8): 1093-4.
42. Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy? Psychopharmacol Bull 1991; 27(2): 103-6.
43. Gilmore DL, Liu Y, Matsumoto RR. Review of the pharmacological and clinical profile of rimcazole. CNS Drug Rev 2004; 10(1): 1-22.
44. Laggner C, Schieferer C, Fiechtner B, Poles G, Hoffmann RD, Glossmann H, et al. Discovery of high-affinity ligands of sigmal receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening. J Med Chem 2005; 48(15): 4754-64.
45. Glennon RA. Pharmacophore identification for sigma-1 (sigmal) receptor binding: application of the "deconstrucion-reconstruction-elaboration" approach. Mini Rev Med Chem 2005; 5(10): 927-40.
46. Gund TM, Floyd J, Jung D. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations. J Mol Graph Model 2004; 22(3): 221-30.
47. Jung D, Floyd J, Grund TM. A comparative molecular field analysis (CoMFA) study using semiempirical, density functional, ab initio methods and pharmacophore derivation using DISCOtech on sigma 1 ligands. J Comput Chem 2004; 25(11): 1385-99.
48. Dence CS, John CS, Bowen WD, Welch MJ. Synthesis and evaluation of [18F] labeled benzamides: high affinity sigma receptor ligands for PET imaging. Nucl Med Biol 1997; 24(4): 333-40.
49. John CS, Gulden ME, Vilner BJ, Bowen WD. Synthesis, in vitro validation and in vivo pharmacokmetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. Nucl Med Biol 1996; 23(6): 761-6.
50. Shiue CY, Shiue GG, Zhang SX, Wilder S, Greenberg JH, Benard F, et al. N-(N-benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: a potential ligand for PET imaging of sigma receptors. Nucl Med Biol 1997; 24(7): 671-6.
51. Waterhouse RN, Slifstein M, Talbot P, Dumont F, Sultana A, Sudo Y, et al. Development of [F-18]1-(3-Fluoropropyl)-4-[(4-cyano-methoxy)methyl]piperidine ([F-18]FPS): An Effective PET Tracer for Imaging Sigma-1 Receptors in the Primate CNS. Annual Meeting of the Academy of Molecular Meeting Orlando, Florida, October 23-27, 2002.
52. Waterhouse RN, Slifstein M, Talbot P, Dumont F, Sultana A, Sudo Y, et al. Validation of [F-18]1-(3-fluoropropyl)-4-[(4-cyanomethoxy)methyl]piperidine ([F-18]FPS) as an Effective PET Tracer for Measurement of Sigma-1 Receptors in the Primate Brain. NeuroImage 2002; 16(3): S6.
53. Shiue C, Shine GG, Benard F, Visonneau S, Santoli D, Alavi AA. N-(n-Benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: a potential ligand for PET imaging of breast cancer. Nucl Med Biol 2000; 27(8): 763-7.
54. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res 1999; 59(18): 4578-83.
55. John CS, Gulden ME, Li J, Bowen WD, McAfee JG, Thakur ML. Synthesis, in vitro binding, and tissue distribution of radioiodinated 2-[125I]N-(N-benzylpiperidin-4-yl)-2-iodo benzamide, 2-[125I]BP: a potential sigma receptor marker for human prostate tumors. Nucl Med Biol 1998; 25(3): 189-94.
56. Choi SR, Yang B, Plossl K, Chumpradit S, Wey SP, Acton PD, et al. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol 2001; 28(6): 657-66.
57. Caveliers V, Everaert H, John CS, Lahoutte T, Bossuyt A. Sigma receptor scintigraphy with N-[2-(1′-piperidinyl)ethyl]-3-(123)I-odo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results. J Nucl Med 2002; 43(12): 1647-9
58. Everaert H, Flamen P, Franken PR, Verhaeghe W, Bossuyt A. Sigma-receptor imaging by means of 1123-IDAB scintigraphy: clinical application, in melanoma and non-small cell lung cancer. Anticancer Res 1997; 17(3B): 1577-82.
59. de Costa B, Radesca L, Dominguez C, Di Paolo L, Bowen WD. Synthesis and receptor binding properties of fluoro- and iodo-substituted high affinity sigma receptor ligands: identification of potential PET and SPECT sigma receptor imaging agents. J Med Chem 1992; 35(12): 2221-30.
60. Huang Y, Hammond PS, Whirrett BF, Kuhner RJ, Wu L, Childers SR, et al. Synthesis and quantitative structure-activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective sigmal receptor ligands. J Med Chem 1998; 41(13): 2361-70.
61. Waterhouse RN, Lombardo I, Simpson N, Kegeles LS, Laruelle M. Evaluation of the Novel Sigma-1 Receptor Radioligand 1-(3-[F-18]Fluopropyl)-4-[(4-cyanophenoxy)methyl]piperidine, [F-18] FPS: PET Imaging Studies in Baboons. Neuroimage 2000; 11(6): S22.
62. Shiue CY, Bai LQ, Shiue GG, Rysavy JA, Pleus RC, Hui H, et al. Synthesis of (+/-)-[18F]BMY 14802, its enantiomers and their anatomical distributions in rodents. Nucl Med Biol 1993; 20(5): 625-30.
63. Waterhouse RN, Chapman J, Izard B, Donald A, Belbin K, O'Brien JC, et al. Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models. Nucl Med Biol 1997; 24(6): 587-93.
64. Wilson AA, Dannals RF, Ravert HT, Souders MS, Weber E, Wagner HN JR. Radiosynthesis of sigma receptor ligands for positron emission tomography: 11C- and 18F-labeled guanidines. J Med Chem 1991; 34(6): 1867-70.
65. John CS, Lim BB, Vilner BJ, Geyer BC, Bowen WD. Substituted halogenated arylsulfonamides: a new class of sigma receptor binding tumor imaging agents. J Med Chem 1998; 41(14): 2445-50.
66. Zamora PO, Moody TW, John CS. Increased binding to sigma sites of N-[1′(2-piperidinyl)ethyl)-4-[I-125]-iodobenzamide (I-125-PAB) with onset of tumor cell proliferation. Life Sci 1998; 63(18): 1611-8.
67. Eisenhut M, Hull WE, Mohammed A, Mier W, Lay D, Just W, et al. Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem 2000; 43(21): 3913-22.
68. Collier TL, O'Brien JC, Waterhouse RN. Syntheis of [F-18]-1-(3-fluoropropyl)-4-[(4-cyanophenoxy) methylpiperidine]: A potential sigma-1 receptor radioligand for PET. J Labelled Cmpds Radiopharm 1996; 37(9): 785-94.
69. Waterhouse RN, Collier TL, O'Brien JC. Synthesis of a selective sigma receptor radioligand for SPECT: [123I]-1-(2-hydroxyethyl)-4-[(4-iodophenoxy) methyl]piperidine. J Labelled Compd and Radiopharm 1996; 38: 595-605.
70. Waterhouse RN, VanBrocklin HF, Hanrahan SM, Eberling JL, Jordan S, Jagust WJ. Pharmacological and SPECT evaluation of [I-123]TPCNE, a selective radioligand for the sigma-1 receptor. J Nucl Med 1996; 37: 374P.
71. Waterhouse RN, Collier TL. In vivo evaluation of [18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl) piperidine: a selective sigma-1 receptor radioligand for PET. Nucl Med Biol 1997; 24(2): 127-34.
72. Waterhouse RN, Mardon K, Giles KM, Collier TL, O'Brien JC. Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for sigma-1 receptors: in vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy) methyl]piperidine. J Med Chem 1997; 40(11):1657-67.
73. Waterhouse RN, Mardon K, O'Brien JC. Synthesis and preliminary evaluation of [123I]1-(4-cyanobenzyl)-4- (trans-iodopropen-2-yl) oxy]methyl]piperidine: a novel high affinity sigma receptor radio-ligand for SPECT. Nucl Med Biol 1997; 24(1): 45-51.
74. Arstad E, Stone JS, Erlandsson K, Waterhouse RN, Norbury R, Ell PJ, et al. [123I]TPCNE - A novel SPET tracer for the sigma-1 receptor: First human studies. Neuroimage 2004; 22(Suppl 2): T100.
75. Waterhouse RN, Nobler MS, Chang RC, Zhou Y, Morales O, Kuwabawa H, et al. First evaluation of the sigma-1 receptor radio-ligand ([18F]1-3-fluoropropyl-4-((4-cyanophenoxy)-methyl)piperidine ([18F]FPS) in healthy humans. Neuroimage 2004; 22(Suppl 2): T29-T30.
76. Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry 2004; 37(Suppl 3): S214-20.
77. Elsinga PH, Kawamura K, Kobayashi T, Tsukada H, Senda M, Vaalburg W, et al. Synthesis and evaluation of [18F]fluoroethyl SA4503 as a PET ligand for the sigma receptor. Synapse 2002; 43(4): 259-67.
78. Fujimura K, Matsumoto J, Niwa M, Kobayashi T, Kawashima Y, In Y, et al. Synthesis, structure and quantitative structure-activity relationships of sigma receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines. Bioorg Med Chem 1997; 5(8): 1675-83.
79. Horan B, Gardner EL, Dewey SL, Brodie JD, Ashby CR. The selective sigma(1) receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(phenylpropyl)piperazine (SA4503), blocks the acquisition of the conditioned place preference response to (-)-nicotine in rats. Eur J Pharmacol 2001; 426(1-2): R1-2.
80. Horan B, Gifford AN, Matsuno K, Mita S, Ashby CR. Effect of SA4503 on the electrically evoked release of (3)H-acetylcholine from striatal and hippocampal rat brain slices. Synapse 2002; 46(1): 1-3.
81. Ishiwata K, Kobayashi T, Kawamura K, Matsuno K, Senda M. [11C]Raclopride binding was reduced in vivo by sigma(1) receptor ligand SA4503 in the mouse brain, while [11C]SA4503 binding was not by raclopride. Nucl Med Biol 2001; 28(7): 787-92.
82. Kawamura K, Ishiwata K, Tajima H, Ishii S, Shimada Y, Matsuno K, et al. Synthesis and in vivo evaluation of [11C]SA6298 as a PET sigma1 receptor ligand. Nucl Med Biol 1999; 26(8): 915-22.
83. Matsuno K. Anti-amnesic effects of sigma (sigma)-receptor agonists. Nippon Yakurigaku Zasshi Japanese J Pharmacol 1999; 114(1): 25-33.
84. Maurice T, Privat A. SA4503, a novel cognitive enhancer with sigma1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur J Pharmacol 1997; 328(1): 9-18.
85. Maurice T, Su TP, Privat A. Sigma 1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 1998; 83(2): 413-28.
86. Minabe Y, Matsuno K, Ashby CR. Acute and chronic administration of the selective sigma1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse 1999; 33(2): 129-40.
87. Nakazawa M, Matsuno K, Mita S. Activation of sigma1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures. Neurochem Int 1998; 32(4): 337-43.
88. Nakazawa M, Kobayashi T, Matsuno K, Mita S. Possible involvement of a sigma receptor subtype in the neck dystonia in rats. Pharmacol Biochem Behav 1999; 62(1): 123-6.
89. Noda A, Noda Y, Kamei H, Ichihara K, Mamiya T, Nagai T, et al. Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors. Neuropsychopharmacology 2001; 24(4): 451-60.
90. Senda T, Matsuno K, Okamoto K, Kobayashi T, Nakata K, Mita S. Ameliorating effect of SA4503, a novel sigma 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. Eur J Pharmacol 1996; 315(1): 1-10.
91. Senda T, Matsuno K, Kobayashi T, Nakazawa M, Nakata K, Mita S. Ameliorative effect of SA4503, a novel cognitive enhancer, on the basal forebrain lesion-induced impairment of the spatial learning performance in rats. Pharmacol Biochem Behav 1998; 59(1): 129-34.
92. Senda T, Mita S, Kaneda K, Kikuchi M, Akaike A. Effect of SA4503, a novel sigma1 receptor agonist, against glutamate neurotoxicity in cultured rat retinal neurons. Eur J Pharmacol 1998; 342(1): 105-11.
93. Skuza G, Rogózring; Z, Wieczorek A. Neuropsychopharmacological profile of remoxipride in comparison with clozapine. Polish J Pharmacol 1997; 49(1): 5-15.
94. Skuza G. Combined treatment with NMDA antagonist, CGP 37849, and sigma receptor agonists, SA4503 or DTG, decreases the neuroleptic-induced catalepsy in rats. Polish J Pharmacol 52(4): 313-6.
95. Tokuyama S, Hirata K, Ide A, Ueda H. Sigma ligands stimulate GTPase activity in mouse prefrontal membranes: evidence for the existence of metabotropic sigma receptor. Neurosci Lett 1997; 233(2-3): 141-4.
96. Ueda H, Inoue M, Yoshida A, Mizuno K, Yamamoto H, Maruo J, et al. Metabotropic neurosteroid/sigma-receptor involved in stimulation of nociceptor endings of mice. J Pharmacol Exp Ther 2001; 298(2): 703-10.
97. Ukai M, Maeda H, Nanya Y, Kameyama T, Matsuno K. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 1998; 61(3): 247-52.
98. Zou LB, Yamada K, Nabeshima T. Sigma receptor ligands (+)-SKF10,047 and SA4503 improve dizocilpine-induced spatial memory deficits in rats. Eur J Pharmacol 1998; 355(1): 1-10.
99. Zou LB, Yamada K, Sasa M, Nakata Y, Nabeshima T. Effects of sigma(1) receptor agonist SA4503 and neuroactive steroids on performance in a radial arm maze task in rats. Neuropharmacology 2000; 39(9): 1617-27.
100. Tottori K, Miwa T, Uwahodo Y, Yamada S, Nakai M, Oshiro Y, et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 2001; 41(8): 976-88.
101. Tottori K, Nakai M, Uwahodo Y, Miwa T, Yamada S, Oshiro Y, et al. Attenuation of scopolamine-induced and age-associated memory impairments by the sigma and 5-hydroxytryptamine(1A) receptor agonist OPC-14523 (1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro- 2[1H]-quinolinone monomethanesulfonate). J Pharmacol Exp Ther 2002; 301(1): 249-57.
102. Casellas P, Bourrie B, Canat X, Carayon P, Buisson I, Paul R, et al. Immunopharmacological profile of SR 31747: in vitro and in vivo studies on humoral and cellular responses. J Neuroimmunol 1994; 52(2): 193-203.
103. Carayon P, Bouaboula M, Loubet JF, Bourrie B, Petitpretre G, Le Fur G, et al. The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-gamma and GM-CSF mRNA expression. Int J Immunopharmacol 1995; 17(9): 753-61.
104. Walker JM, Bowen WD, Goldstein SR, Roberts AH, Patrick SL, Hohmann AG, et al. Autoradiographic distribution of [3H](+)-pentazocine and [3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: a comparative study. Brain Res 1992; 581(1): 33-8.
105. Bouchard P, Quirion R. [3H]1,3-di(2-tolyl)guanidine and [3H](+) pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 1997; 76(2): 467-77.
106. Jansen KL, Faull RL, Dragunow M, Leslie RA. Autoradiographic distribution of sigma receptors in human neocortex, hippocampus, basal ganglia, cerebellum, pineal and pituitary glands. Brain Res 1991; 559(1): 172-7.
107. Jansen KL, Dragunow M, Faull RL. Sigma receptors are highly concentrated in the rat pineal gland. Brain Res 1990; 507(1): 158-60.
108. Mash DC, Zabetian CP. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse 1992; 12(3): 195-205.
109. Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl) piperidine. J Neurosci 1986; 6(6): 1757-70.
110. Gundlach AL, Largent BL, Snyder SH. Phencyclidine and sigma opiate receptors in brain: biochemical and autoradiographical differentiation. Eur J Pharmacol 1985; 113(3): 465-6.
111. Wolfe SA Jr, De Souza EB. Sigma and phencyclidine receptors in the brain-endocrine-immune axis. NIDA Res Monogr 1993; 133: 95-123.
112. Wolfe SA Jr, Culp SG, De Souza EB. Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 1989; 124(3): 1160-72.
113. Largent BL, Gundlach AL, Snyder SH. Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)peridine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J Pharmacol Exp Ther 1986; 238(2): 739-48.
114. Ujike H, Akiyama K, Kuroda S. [3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes. Neuroreport 1996; 7(5): 1057-61.
115. Heroux JA, Tam SW, De Souza EB. Autoradiographic identification and characterization of sigma receptors in guinea pig brain using [3H]1(cyclopropylmethyl)-4-(2′-(4″-fluorophenyl)-2′- oxoethyl) piperidine ([3H]DuP 734), a novel sigma receptor ligand. Brain Res 1992; 598(1-2): 76-86.
116. Itzhak Y, Stein I. Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. Life Sci 1990; 47(13): 1073-81.
117. Soby KK, Mikkelsen JD, Meier E, Thomsen C. Lu 28-179 labels a sigma(2)-site in rat and human brain. Neuropharmacology 2002; 43(1): 95-100.
118. John CS, Bowen WD, Varma VM, McAfee JG, Moody TW. Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sci 1995; 56(26): 2385-92.
119. Itzhak Y, Alerhand S. Differential regulation of sigma and PCP receptors after chronic administration of haloperidol and phencyclidine in mice. FASEB J 1989; 3(7): 1868-72.
120. Okuyama S, Imagawa Y, Ogawa S, Araki H, Ajima A, Tanaka M, et al. NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci 1993; 53(18): PL285-90.
121. Okuyama S, Imagawa Y, Sakagawa T, Nakazato A, Yamaguchi K, Katoh M, et al. NE-100, a novel sigma receptor ligand: effect on phencyclidine-induced behaviors in rats, dogs and monkeys. Life Sci 1994; 55(7): PL133-8.
122. Okuyama S, Ogawa S, Nakazato A, Tomizawa K. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine- induced delayed cognitive dysfunction in rats. Neurosci Lett 1995; 189(1): 60-2.
123. Ogawa S, Okuyama S, Araki H, Otomo S. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur J Pharmacol 1994; 263(1-2): 9-15.
124. Ogawa S, Okuyama S, Tsuchida K, Araki H, Otomo S. The sigma-selective ligand NE-100 attenuates the effect of phencyclidine in a rat diving model. General Pharmacol 1995; 26(1): 177-82.
125. Rupprecht R, Hauser CA, Trapp T, Holsboer F. Neurosteroids: Molecular mechanisms of action and psychopharmacological significance. J Steroid Biochem Mol Biol 1996; 56: 163-8.
126. Wehling M. Nongenomic actions of steriod hormones. Trends Endocrinol Metab 1994; 5: 347-53.
127. Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 1997; 52: 1-32.
128. Baulieu EE. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 1998; 23(8): 963-87.
129. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 1996; 16(3): 1193-202.
130. Debonnel G, Bergeron R, de Montigny C. Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. J Endocrinol 1996; 150 Suppl: S33-42.
131. Maurice T, Junien JL, Privat A. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma 1-receptors. Behav Brain Res 1997; 83(1-2): 159-64.
132. Maurice T, Roman FJ, Privat A. Modulation by neurosteroids of the in vivo (+)-[3H]SKF-10,047 binding to sigma 1 receptors in the mouse forebrain. J Neurosci Res 1996; 46(6): 734-43.
133. Maurice T, Su TP, Privat A. Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 1998; 83(2): 413-28.
134. Monnet FP, Mahé V, Robel P, Baulieu EE. Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA 1995; 92(9): 3774-8.
135. Phan VL, Su TP, Privat A, Maurice T. Modulation of steroidal levels by adrenalectomy/castration and inhibition of neurosteroid synthesis enzymes affect sigma1 receptor-mediated behaviour in mice. Eur J Neurosci 1999; 11(7): 2385-96.
136. Schwarz S, Pohl P, Zhou GZ. Steroid binding at sigma-opioid receptors. Science 1989; 246(4937): 1635-8.
137. Urani A, Privat A, Maurice T. The modulation by neurosteroids of the scopolamine-induced learning impairment in mice involves an interaction with sigma1 (sigma1) receptors. Brain Res 1998; 799(1): 64-77.
138. Cabrera RJ, Navarro CE. Progesterone in vitro increases NMDA-evoked [3H] dopamine release from striatal slices in proestrus rats. Neuropharmacology 1996; 35(2): 175-8.
139. Cabrera R, Díaz A, Pinter A, Belmar J. In vitro progesterone effects on 3H-dopamine release from rat corpus striatum slices obtained under different endocrine conditions. Life Sci 1993; 53(23): 1767-77.
140. Cabrera RJ, Bregonzio C. Turnover rate and stimulus-evoked release of dopamine by progesterone and N-methyl-D-aspartic acid in rat striatum during pregnancy. Eur J Pharmacol 1996; 317(1): 55-9.
141. Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotrammissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996; 58(9): 721-34.
142. Debonnel G. Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J Psychiat Neurosci 1993; 18(4): 157-72.
143. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiat 2003; 60(2): 133-41.
144. Waterhouse RN, Atuahene N, Balter A, Collier TL. Effect of Neuroactive Steroids on the In Vitro and In Vivo Binding of the Sigma-1 Receptor PET Radioligand [18F]FPS. J Cerebral Blood Flow Metabol 2003; 23: 699.
145. Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima. T. Neuroactive neurosteroids as endogenous effectors for the sigmal (sigmal) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 1999; 81(2): 125-55.
146. Ferris RM, Tang FL, Chang KJ, Russell A. Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci 1986; 38(25): 2329-37.
147. Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, et al. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 1994; 10(1): 37-40.
148. Ahlfors UG, Rimön R, Appelberg B, Hagert U, Harma P, Katila H, et al. Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Acta Psychiat Scand Suppl 1990; 358: 99-103.
149. Den Boer JA, Ravelli DP, Huisman J, Ohrvik J, Verhoeven WM, Westenberg HG. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology 1990; 102(1): 76-84.
150. den Boer JA, Westenberg HG. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol. Psychopharmacol Bull 1990; 26(1): 99-107.
151. Laux G, Klieser E, Schröder HG, Dittmann V, Unterweger B, Schubert H, et al. A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Acta Psychiat Scand Suppl 1990; 358: 125-9.
152. Lewander T, Westerbergh SE, Morrison D. Clinical profile of remoxipride - a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiat Scand Suppl 1990; 358: 92-8.
153. Chouinard G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiat Scand Suppl 1990; 358: 111-9.
154. Okuyama S, Imagawa Y, Sakagawa T, Nakazato A, Yamaguchi K, Katoh M, et al. NE-100, a novel sigma receptor ligand: effect on phencyclidine-induced behaviors in rats, dogs and monkeys. Life Sci 1994; 55(7): PL133-8.
155. Frieboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 1997; 132(1): 82-8.
156. Frieboes RM, Murck H, Antonijevic I, Kraus T, Hinze-Selch D, Pollmacher T, et al. Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by
157. Modell S, Naber D, Holzbach R. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Pharmacopsychiatry 1996; 29(2): 63-6.
158. Ding YS, Fowler JS, Dewey SL, Wolf AP, Logan J, Gatley SJ, et al. Synthesis and PET studies of fluorine-18-BMY 14802: a potential antipsychotic drug. J Nucl Med 1993; 34(2): 246-54.
159. Schlyer DJ, Volkow ND, Fowler JS, Wolf AP, Shiue CY, Dewey SL, et al. Regional distribution and kinetics of haloperidol binding in human brain: a PET study with [18F]haloperidol. Synapse 1992; 11(1): 10-9.
160. Yousef KA, Fowler JS, Volkow ND, Dewey SL, Shea C, Schlyer DJ, et al. [18F]haloperidol binding in baboon brain in vivo. Nucl Med Biol 1996; 23(1): 47-52.
161. Huber MT, Gotthardt U, Schreiber W, Krieg JC. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry 1999; 32(2): 68-72.
162. Carroll FI, Howell LL, Kuhar MJ. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 1999; 42: 2721-36.
163. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1998; 1: 132-7.
164. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, et al. Cacaine reward models: conditioned place preference can be established in dopamine and serotonin-transporter knockout mice. Proc Natl Acad Sci USA 1998; 95: 7690-704.
165. Ritz MC, George FR. Cocaine-induced seizures and lethality appear to be associated with distinct central nervous system binding sites. J Pharmacol Exp Ther 1993; 264: 1333-43.
166. Sharkey J, Glen KA, Wolfe S, Kuhar MJ. Cocaine binding at σ receptors. Eur J Pharmacol 1988; 149: 171-4.
167. 1) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002; 26: 499-527.
168. Goldstein SR, Matsumoto RR, Thompson TL, Patrick RL, Bowen WD, Walker JM. Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 1989; 4: 254-8.
169. Iyengar S, Dilworth VM, Mick SJ, Contreras PC, Monahan JB, Rao TS, et al. Sigma receptors modulate both A9 and A10 dopaminergic neurons in the rat brain: functional interaction with NMDA receptors. Brain Res 1990; 524: 322-6.
170. 3H]dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther 1994; 271: 212-9.
171. 3H]dopamine release via a presynaptic mechanism. Eur J Pharmacol 1995; 294: 713-9.
172. Liu X, Kassiou M, Christie MJ, Hambley TW. Trishomocubanes: requirements for σ receptor binding and subtype selectivity. Aust J Chem 2001; 54: 31-6.
173. 3H]dopamine release. Eur J Pharmacol 2001; 422: 39-45.
174. Wachtel SR, White FJ. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies. J Pharmacol Exp Ther 1988; 224: 410-6.
175. Steinfels GF, Alberici GP, Tam SW, Cook L. Biochemical, behavioral, and electrophysiologic actions of the selective sigma receptor ligand (+)pentazocine. Neuropsychopharmacology 1988; 1: 321-7.
176. Steinfels GF, Tam SW, Cook L. Electrophysiological effects of selective sigma receptor agonists, antagonists, and the selective phencyclidine receptor agonist MK-801 on midbrain dopamine neurons. Neuropsychopharmacology 1989; 2: 201-8.
177. Steinfels GF, Tam SW. Selective σ receptor agonist and antagonist affect dopamine neuronal activity. Eur J Pharmacol 1989; 163: 167-70.
178. 2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles. J Pharmacol Exp Ther 1992; 263: 1167-74.
179. Cook L, Tam SW, Rohrbach KW. DuP 734 [1-(cyclopropylmethyl)-4-(2′- (4″-fluorophenyl)-2′-oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects. J Pharmacol Exp Ther 1992; 263: 1159-66.
180. Matsumoto RR, McCraken KA, Pouw B, Miller J, Bowen WD, Williams W, et al. N-alkyl substituted analogs of the σ receptor ligand BD1008 and traditional σ receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur J Pharmacol 2001; 411: 261-73.
181. McCraken KA, Bowen WD, de Costa BR, Matsumoto RR. Two novel σ receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur J Pharmacol 1999; 370: 225-32.
182. Matsumoto RR, McCraken KA, Pouw B, Zhang Y, Bowen WD. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002; 42: 1043-55.
183. Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ. σ receptors: potential medications development target for anticocaine agents. Eur J Pharmacol 2003; 469: 1-12.
184. Herdegen T, Leah JD. Inducible and constructive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF protiens. Brain Res Rev 1998; 28: 370-490.
185. Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005; 97(3): 317-36.
186. Dubrovsky BO. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuro Psychopharmacol Biol Psychiat 2005; 29(2): 169-92.
187. Urani A, Romieu P, Roman FJ, Yamada K, Noda Y, Kamei H, et al. Enhanced antidepressant efficacy of sigmal receptor agonists in rats after chronic intracerebroventricular infusion of beta-amyloid(1-40) protein. Eur J Pharmacol 2004; 486(2): 151-61.
188. Skuza G, Wedzony K. Behavioral pharmacology of sigma-ligands. Pharmacopsychiatry 2004; 37(Suppl 3): S183-8.
189. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology 2004; 174(3): 301-19.
190. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18(5): 269-84.
191. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology 2003; 165(2): 97-110.
192. Skuza G. Potential antidepressant activity of sigma ligands. Polish J Pharmacol 2003; 55(6): 923-34.
193. Urani A, Roman FJ, Phan VL, Su TP, Maurice T. The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001; 298(3): 1269-79.
194. Urani A, Romieu P, Roman FJ, Maurice T. Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice. Behav Brain Res 2002; 134(1-2): 239-47.
195. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003; 10(20): 2073-80.
196. Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry 2004; 37(Suppl 3): S214-20.
197. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectrums 2005; 10(4): 319-23.
198. Fabian TJ, Dew MA, Pollock BG, Reynolds CF, 3rd, Mulsant BH, Butters MA, et al. Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults. Biol Psychiat 2001; 50(10): 767-74.
199. Maurice T, Phan VL, Urani A, Guillemain I. Differential involvement of the sigma(1) (sigma(1)) receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse. Br J Pharmacol 2001; 134(8): 1731-41.
200. Maayan R, Morad O, Dorfman P, Overstreet DH, Weizman A, Yadid G. The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depression. Eur Neuropsychopharmacol 2005; 15(3): 253-62.
201. Frye CA, Sturgis JD. Neurosteroids affect spatial/reference, working, and long-term memory of female rats. Neurobiol Learning Memory 1995; 64(1): 83-96.
202. Genazzani AR, Inglese S, Lombardi I, Pieri M, Bernardi F, Genazzani AD, et al. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency. Aging Male 2004; 7(2): 133-43.
203. Rupprecht R, Holsboer F. Neuropsychopharmacological properties of neuroactive steroids. Steroids 1999; 64(1-2): 83-91.
204. Sondergaard HP, Hansson LO, Theorell T. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in post-traumatic stress disorder: findings from a longitudinal study of refugees in Sweden. Psychother Psychosom 2002; 71(5): 298-303.
205. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiat 2003; 60(2): 133-41.
206. Takebayashi M, Hayashi T, Su TP. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 2004; 37(Suppl 3): S208-13.
207. Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metabol 1998; 83(9): 3130-3.
208. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiat 2005; 62(2): 154-62.
209. Maayan R, Yagorowski Y, Grupper D, Weiss M, Shtaif B, Kaoud MA, et al. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol Psychiat 2000; 48(7): 693-701.
210. Zhang H, Cuevas J. sigma Receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J Pharmacol Exp Ther 2005; 313(3): 1387-96.
211. Novakova M, Ela C, Bowen WD, Hasin Y, Eilam Y. Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Eur J Pharmacol 1998; 353(2-3): 315-27.
212. Lishmanov Yu B, Maslov LN, Naryzhnaya NV, Tam SW. Ligands for opioid and sigma-receptors improve cardiac electrical stability in rat models of post-infarction cardiosclerosis and stress. Life Sci 1999; 65(1): PL13-7.
213. Lishmanov Iu B, Maslov LN, Tam SV, Bogomaz SA. Opioid system and cardiac resistance to ischemic and reperfusion injuries. Ross Fiziol Zh Im I M Sechenova 2000; 86(2): 164-73.
214. Maslov LN, Lishmanov Iu B, Naryzhnaia NV, Krylatov AV, Tam SV. Ligands of opioid and sigma receptors and correction of cardiac electrical instability in post-infarction cardiosclerosis. Eksp Klin Farmakol 2001; 64(1): 38-41.
215. Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Sigma receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 1994; 269(3): 1300-9.
216. Ela C, Hasin Y, Eilam Y. Apparent desensitization of a sigma receptor sub-population in neonatal rat cardiac myocytes by pretreatment with sigma receptor ligands. Eur J Pharmacol 1996; 295(2-3): 275-80.
217. Novakova M, Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur J Pharmacol 1995; 286(1): 19-30.
218. Novakova M, Ela C, Bowen WD, Hasin Y, Eilam Y. Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Eur J Pharmacol 1998; 353(2-3): 315-27.
219. YuB L, Maslov LN, Naryzhnaya NV, Tam SW. Ligands for opioid and sigma-receptors improve cardiac electrical stability in rat models of post-infarction cardiosclerosis and stress. Life Sci 1999; 65(1): PL13-7.
220. Maslov LN, IuB L, Bogomaz SA, Gilligan P, Tam SW. Dependence of the pump function of the isolated rat heart on the functional activity of sigma receptors during reperfusion. Ross Fiziolzh Im I M Sechenova 1999; 85(11): 1396-408.
221. Mittleman MA, Mintzer D, Maclure M, Tofler GH, Sherwood JB, Muller JE. Triggering of myocardial infarction by cocaine. Circulation 1999; 99(21): 2737-41.
222. Wilbert-Lampen U, Seliger C, Zilker T, Arendt RM. Cocaine increases the endothelial release of immunoreactive endothelin and its concentrations in human plasma and urine: reversal by coincubation with sigma-receptor antagonists. Circulation 1998; 98(5): 385-90.
223. Hwang DM, Dempsey AA, Wang RX, Rezvani M, Barrans JD, Dai KS, et al. A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. Circulation 1997; 96(12): 4146-203.
224. Waterhouse RN, Collier TL. In vivo evaluation of [18F]1-(3-fluoropropyl)- 4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET. Nucl Med Biol 1997; 24(2): 127-34.
225. Jerusalem G, Hustinx R, Beguin Y, Fillet G. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol 2002; 13(Suppl 4): 227-34.
226. Czernin J. Clinical applications of FDG-PET in oncology. Acta Medica Austriaca 2002; 29(5): 162-70.
227. Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003; 23(2): 315-40.
228. Maublant J, Vuillez JP, Talbot JN, Lumbroso J, Muratet JP, Herry JY, et al. Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology. Bull Cancer 1998; 85(11): 935-50.
229. Kubota K. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001; 15(6): 471-86.
230. Turkington TG, Coleman RE. Clinical oncologic positron emission tomography: an introduction. Semin Roentgenol 2002; 37(2): 102-9.
231. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 2000; 27(7): 683-7.
232. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996; 37(6): 1042-7.
233. Ding HJ, Shiau YC, Wang JJ, Ho ST, Kao A. The influences of blood glucose and duration of fasting on myocardial glucose uptake of [18F]fluoro-2-deoxy-D-glucose. Nucl Med Commun 2002; 23(10): 961-5.
234. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 2003; 63(14): 3847-54.
235. Haaparanta M, Paul R, Gronroos T, Bergman J, Kamarainen EL, Solin O. Microdialysis and 2-[18F]fluoro-2-deoxy-D-glucose (FDG): a study on insulin action on FDG transport, uptake and metabolism in rat muscle, liver and adipose tissue. Life Sci 2003; 73(11): 1437-51.
236. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998; 25(4): 317-22.
237. Pauwels EK, Sturm EJ, Bombardieri E, Cleton FJ, Stokkel MP. Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 2000; 126(10): 549-59.
238. Wienhard K. Measurement of glucose consumption using [(18)F] fluorodeoxyglucose. Methods 2002; 27(3): 218-25.
239. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 2001; 31(1): 43-56.
240. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 2003; 19(1): 61-77.
241. Zimny M, Kaiser HJ, Wildberger J, Nowak B, Cremerius U, Sabri O, et al. Analysis of FDG uptake with hybrid PET using standardised uptake values. Eur J Nucl Med 2001; 28(5): 586-92.
242. Sugawara Y, Gutowski TD, Fisher SJ, Brown RS, Wahl RL. Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67Ga-citrate, and 1251-HSA. Eur J Nucl Med 1999; 26(4): 333-41.
243. Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 1998; 25(9): 1238-43.
244. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000; 27(7): 643-6.
245. Kofoed KF, Hove JD, Freiberg J, Host U, Holm S, Kelbaek H. Variability of insulin-stimulated myocardial glucose uptake in healthy elderly subjects. Eur J Nucl Med Mol Imaging 2002; 29(12): 1600-7.
246. Inoue T, Oriuchi N, Tomiyoshi K, Endo K. A shifting landscape: what will be next FDG in PET oncology? Ann Nucl Med 2002; 16(1): 1-9.
247. Mankoff DA, Bellon JR. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol 2001; 11(1): 16-27.
248. Wahl RL. Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol 2001; 36(3): 250-60.
249. Minosako Y, Nemoto M, Ino S, Shirakami Y, Kurami M. Uptake of FDG (2-fluoro-2-deoxy-D-glucose) as a tumor imaging agent into erythrocytes and accumulation of FDG in tumor cells. Kaku Igaku the Japanese J Nucl Med 2003; 40(1): 23-30.
250. Osman MM, Cohade C, Nakamoto Y, Marshall LT, Leal JP, Wahl RL. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 2003; 44(2): 240-3.
251. Salminen E, Mac Manus M. Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer. Ann Med 2001; 33(6): 404-9.
252. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Japn J Clin Oncol 1999; 29(12): 623-9.
253. Oyen WJ, Witjes JA, Corstens FH. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Eur Urol 2001; 40(3): 294-9.
254. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995; 55(2): 408-13.
255. Varagnolo L, Stokkel MP, Mazzi U, Pauwels EK. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl Med Biol 2000; 27(2): 103-12.
256. Hautzel H, Muller Mattheis V, Herzog H, Roden W, Coenen HH, Ackermann R, et al. The (11C) acetate positron emission tomography in prostatic carcinoma. New prospects in metabolic imaging. Urologe A 2002; 41(6): 569-76.
257. Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, et al. Accumulation of [(11)C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29(11): 1492-5.
258. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for restaging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169(4): 1337-40.
259. Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002; 43(2): 187-99.
260. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002; 42(1): 18-23.
261. Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, et al. Positron emission tomography with (11)C-acetate and (18)F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30(4): 607-11.
262. Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002; 43(1): 46-55.
263. Hwang DR, Lang LX, Mathias CJ, Kadmon D, Welch MJ. N-3-[18F]fluoropropylputrescine as potential PET imaging agent for prostate and prostate derived tumors. J Nucl Med 1989; 30(7): 1205-10.
264. Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42(1): 25-30.
265. Hwang DR, Mathias CJ, Welch MJ, McGuire AH, Kadmon D. Imaging prostate derived tumors with PET and N-(3-[18F]fluoropropyl)putrescine. Int J Radiat Appl Instrum B 1990; 17(6): 525-32.
266. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with (11)C-acetate. J Nucl Med 2003; 44(4): 556-8.
267. Wang GJ, Volkow ND, Wolf AP, Madajewicz S, Fowler JS, Schlyer DJ, et al. Positron emission tomography study of human prostatic adenocarcinoma using carbon-11 putrescine. Nucl Med Biol 1994; 21(1): 77-82.
268. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61(1): 110-7.
269. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000; 56(6): 988-93.
270. Fang DX, Stock RG, Stone NN, Krynyckyi BR, Kim CK, Machac J. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy. Tech Urol 2000; 6(2): 146-50.
271. Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate 1998; 37(3): 140-8.
272. Murphy GP, Snow PB, Brandt J, Elgamal A, Brawer MK. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans. Prostate 2000; 42(2): 145-9.
273. Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002; 5(2): 132-5.
274. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 1998; 37(4): 261-9.
275. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 2001; 7(1): 27-37.
276. Jochelson M. Breast cancer imaging: the future. Semin Oncol 2001; 28(3): 221-8.
277. McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32(8): 1526-31.
278. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2(6): 933-9.
279. Rodrigues M, Chehne F, Kalinowska W, Berghammer P, Zielinski C, Sinzinger H. Uptake of 99mTc-MIBI and 99mTc-tetrofosmin into malignant versus nonmalignant breast cell lines. J Nucl Med 2000; 41(9): 1495-9.
280. Talbot JN, Grahek D, Kerrou K, Younsi N, de Beco V, Colombet-Lamau C, et al. (18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers. Gynecol Obstet Fertil 2001; 29(11): 775-98.
281. Tewson TJ, Mankoff DA, Peterson LM, Woo I, Petra P. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 1999; 26(8): 905-13.
282. Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000; 24(2): 274-80.
283. Paz A, Melloul M, Cytron S, Koren R, Ohana G, Michalevich D, et al. The value of early and double phase 99Tcm-sestamibi scintimammography in the diagnosis of breast cancer. Nucl Med Commun 2000; 21(4): 341-8.
284. Chiti A, Agresti R, Maffioli LS, Tomasic G, Savelli G, Crippa F, et al. Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography. Eur J Nucl Med 1997; 24(2): 192-6.
285. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O, et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000; 1(2): 156-61; discussion 162-3.
286. Giorgetti A, Volterrani D, Mariani G. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose. Radiol Med (Torino) 2002; 103(4): 293-318.
287. Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 1998; 42(1): 8-17.
288. Kole AC, Nieweg OE, Pruim J, Paans AM, Plukker JT, Hoekstra HJ, et al. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET. J Nucl Med 1997; 38(5): 692-6.
289. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol 1997; 24(4): 341-8.
290. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003; 44(2): 224-39.
291. Mondal A, Sharma R, Chakravarty KL, Mishra P, Sahay K, Bhatnagar A, et al. Delayed Tc-99m citrate scintigraphy in the evaluation of palpable breast masses. Clin Nucl Med 1999; 24(5): 309-13.
292. Bombardieri E, Crippa F. PET imaging in breast cancer. Q J Nucl Med 2001; 45(3): 245-56.
293. Sauer G, Deissler H, Kurzeder C, Kreienberg R. New molecular targets of breast cancer therapy. Strahlenther Onkol 2002; 178(3): 123-33.
294. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 17(3B): 1573-6.
295. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002; 8(9): 2766-74.
296. Bonhaus DW, Loury DN, Jakeman LB, To Z, DeSouza A, Eglen RM, et al. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus. J Pharmacol Exp Ther 1993; 267(2): 961-70.
297. Mascarella SW, Bai X, Williams W, Sine B, Bowen WD, Carroll FI. (+)-cis-N-(para-, meta-, and ortho-substituted benzyl)-N-normetazocines: synthesis and binding affinity at the [3H]-(+)-pentazocine-labeled (sigma 1) site and quantitative structure-affinity relationship studies. J Med Chem 1995; 38(3): 565-9.
298. Brent PJ, Pang GT. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 1995; 278(2): 151-60.
299. Kedjouar B, Daunes S, Vilner BJ, Bowen WD, Klaebe A, Faye JC, et al. Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor. Biochem Pharmacol 1999; 58(12): 1927-39.
300. Bowen WD. Sigma receptors: recent advances and new clinical potentials. Pharm, Acta Helv 2000; 74(2-3): 211-8.
301. Simony-Lafontaine J, Esslimani M, Bribes E, Gourgou S, Lequeux N, Lavail R, et al. Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br J Cancer 2000; 82(12): 1958-66.
302. John CS, Lim BB, Geyer BC, Vilner BJ, Bowen WD. 99mTc-labeled sigma-receptor-binding complex: synthesis, characterization, and specific binding to human ductal breast carcinoma (T47D) cells. Bioconjug Chem 1997; 8(3): 304-9.
303. Barbieri F, Sparatore A, Alama A, Novelli F, Bruzzo C, Sparatore F. Novel sigma binding site ligands as inhibitors of cell proliferation in breast cancer. Oncol Res 2003; 13(11): 455-61.
304. Vilner BJ, Bowen WD. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur J Pharmacol 1993; 244(2): 199-201.
305. Maneckjee R, Minna JD. Biologically active MK-801 and SKF-10,047 binding sites distinct from those in rat brain are expressed on human lung cancer cells. Mol Biol Cell 1992; 3(6): 613-9.
306. Barg J, Thomas GE, Bem WT, Parnes MD, Ho AM, Belcheva MM, et al. In vitro and in vivo expression of opioid and sigma receptors in rat C6 glioma and mouse N18TG2 neuroblastoma cells. J Neurochem 1994; 63(2): 570-4.
307. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, et al. Overexpression of sigma receptors in nonneural human tumors. Cancer Res 1991; 51(24): 6558-62.
308. Thomas GE, Szucs M, Mamone J, Bem WT, Rush MD, Johnson FE, et al. Sigma and opioid receptors in human brain tumors. Life Sci 1990; 46(18): 1279-86.
309. Gutierrez-Puente Y, Zapata-Benavides P, Tari AM, Lopez-Berestein G. Bcl-2-related antisense therapy. Semin Oncol 2002; 29(3 Suppl 11): 71-6.
310. Alsabeh Rea. Expression of bcl-2 by breast cancer: a possible diagnostic application. Modern Pathol 1996; 9(4): 439-44.
311. Berthois Y, Bourrie B, Galiegue S, Vidal H, Carayon P, Martin PM, et al. SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo. Br J Cancer 2003; 88(3): 438-46.
312. Waterhouse RN, Stabin MG, Page JG. Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel sigma-1 receptor radiotracer [(18)F]FPS. Nucl Med Biol 2003; 30(5): 555-63.
313. Waterhouse RN, Fawwaz R, Atuahene N, Liu L, Schmidt AM, Collier TL. Biodistribution and MicroPET studies of the sigma-1 receptor radiotracer [18F]FPS in the MMTV transgenic breast cancer mouse model. J Nucl Med 2003: SNM Annual Meeting, New Orleans, LA. (J Nucl Med abstracts).
314. Waterhouse RN, Fawwaz R, Collier TL, Dumont F, Lee DC, Schmidt AM, et al. The sigma-1 receptor PET ligand [18F]FPS: potential advantages over [18F]FDG for tumor imaging demonstrated in pre-clinical models. J Nucl Med 2002; 43(5): 280P.
315. Waterhouse RN, Smith MF, Greer KL, Collier TL, Eberl S, Towson J, et al. Pre-clinical SPECT studies to evaluate I-123-HEPIE as a lung cancer imaging agent. J Nucl Med 1998; 39: 227P
316. Wang WF, Ishiwata K, Kiyosawa M, Kawamura K, Oda K, Matsuno K, et al. Investigation of the use of positron emission tomography for neuroreceptor imaging in rabbit eyes. Ophthal Res 2004; 36(5): 255-63.
317. Wang L, Prescott AR, Spruce BA, Sanderson J, Duncan G. Sigma receptor antagonists inhibit human lens cell growth and induce pigmentation. Invest Ophthal Vis Sci 2005; 46(4): 1403-8.
318. Roth MD, Whittaker KM, Choi R, Tashkin DP, Baldwin GC. Cocaine and {sigma}-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model. J Leukoc Biol 2005; 78(6): 1198-203.
319. Gannon CJ, Malone DL, Napolitano LM. Reduction of IL-10 and nitric oxide synthesis by SR31747A (sigma ligand) in RAW murine macrophages. Surg Infect (Larchmt) 2001 Winter; 2(4): 267-72; discussion 73.
320. Vidal H, Mondesert G, Galiegue S, Carriere D, Dupuy PH, Carayon P, et al. Identification and pharmacological characterization of SRBP-2: a novel SR31747A-binding protein. Cancer Res 2003; 63(16): 4809-18.
321. Dolle F. Fluorine-18-labelled fluoropyridines: advances in radiopharmaceutical design. Curr Pharm Des 2005; 11(25): 3221-35.
322. Gatley SJ, Volkow ND, Wang GJ, Fowler JS, Logan J, Ding YS, et al. PET imaging in clinical drug abuse research. Curr Pharm Des 2005; 11(25): 3203-19.
323. Guilloteau D, Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des 2005; 11(25): 3237-45.